4.6 Article

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation

Journal

CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 94, Issue 2, Pages 207-210

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2013.59

Keywords

-

Funding

  1. National Institutes of Health (NIH)/National Institute of General Medical Sciences Pharmacogenomics Research Network [U01 GM92666, U01 HL105198, GM61374, U01 GM92655, U19 HL065962, U19 GM61388, KL2 RR024151, U01 GM074492]
  2. NIH/National Cancer Institute [CA 36401, CA 21765]
  3. American Lebanese Syrian Associated Charities

Ask authors/readers for more resources

The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of implementation best practices will prove useful to a broad audience.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available